Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Abstract Leveraging adaptive tumour immunity to control mesothelioma via immune checkpoint blockade is now a standard therapeutic approach. However, the determinants of sensitivity remain elusive. Low non-synonymous mutation burden and programmed death-ligand 1 expression, an abundance of immunosupp...

Full description

Saved in:
Bibliographic Details
Main Authors: Dean A. Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Essa Y. Baitei, Joanna Dzialo, Nada Nusrat, Jan Rogel, Daniel Faulkner, Christian Ottensmeier, Raffaele Califano, Gerard G. Hanna, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Kim Mallard, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Liz Darlison, Peter Wells-Jordan, Cathy Richards, James Harber, Aleksandra Bzura, Jake Spicer, Catrin Pritchard, Tamihiro Kamata, Jens C. Hahne, Maymun Jama, Edward J. Hollox, Jason F. Lester, Jin-Li Luo, Zisen Zhou, Hongji Yang, Huiyu Zhou, Astero Klampatsa, Gareth O. Griffiths
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61691-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-61691-4

Similar Items